-1753359861743.webp&w=3840&q=75)
2025 NOSCM | Optimal Therapy for Early Stage Triple Negative Breast Cancer
0% Complete
Course Overview
Dr. Hope Rugo emphasized neoadjuvant therapy for TNBC and the role of pembrolizumab.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Hope S. Rugo, MD, FASCO
Accreditation
NA
